STAT1 and colitis: Our findings showed that AS-IV attenuated clinical disease activity, diminished pro-inflammatory cytokine production, up-regulated anti-inflammatory cytokine production, and decreased the percentages of macrophages by blocking the M1 polarization of macrophages partially through the STAT1 signaling pathway in DSS-induced colitis.